

## **Publication**

Nagata et al. 2022 American Journal of Respiratory and Critical Care Medicine


**Home High-Flow Nasal Cannula Oxygen Therapy** for Stable Hypercapnic **COPD: A Randomized Trial** 

## **Objective:**

To assess whether Nasal High Flow (NHF) therapy in the home using the myAirvo<sup>™</sup> 2 and Optiflow<sup>™</sup> cannula — reduces the number of exacerbations and improves other physiological parameters in patients with chronic hypercapnic respiratory failure due to Chronic Obstructive Pulmonary Disease (COPD).

## **Primary Outcome:**

The rate of moderate/severe COPD exacerbations over the 52-week period.



Patients included in full analysis set

# Mean NHF usage

7.3 ± 3.0 Daily Usage (hr/day) (mainly at night) NHF Flow rate 28.5 ± 4.57 (L/min)

34 - 37 **Temperature** (°C) (started on 37)

#### **Moderate COPD Exacerbation**

"... necessitating treatment with systemic corticosteroids and/or antibiotics"

#### **Severe COPD Exacerbation**

"... requiring hospitalization, including an emergency admission"






## Results

NHF/LTOT significantly reduced the rate of moderate/severe COPD exacerbations compared to LTOT alone (unadjusted mean count 1.0 vs. 2.5, a ratio of the adjusted mean count between groups of 2.85 [95% CI; 1.48-5.47], p = 0.002)



NHF prolonged the duration without moderate/severe COPD exacerbations over the 52-week study period (p = 0.0324). The rates (%) of patients without an exacerbation at the 52nd week in the LTOT and NHF/LTOT groups were 35.9 and 56.1, respectively.

#### Time to first moderate or severe COPD exacerbation





### NHF also significantly improved (p < 0.05):

- SGRQ-C total score at week 24
- SGRQ-C impact score at week 12
- SpO<sub>2</sub> at week 52
- PaCO<sub>2</sub> at week 12
- FVC (%FVC) at week 24
- FEV1 (%FEV1) at week 12

LTOT = long term oxygen therapy

CI = confidence interval

SGRQ-C = St George's Respiratory Questionnaire for COPD

SpO<sub>2</sub> = peripheral oxygen saturation FVC = forced vital capacity FEV1 = forced expiratory volume in 1 s

Further reading







**Key Points** 

NHF in the home significantly reduced the rate of moderate/ severe exacerbations

NHF in the home prolonged the duration without moderate/ severe exacerbations